ENTERO THERAPEUTICS INC (ENTO) Stock Analyst Earnings Estimates
NASDAQ:ENTO - Nasdaq - US33749P4081 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A 178.96% | N/A 90.20% | ||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | -56.163M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A -31.90% | N/A -16.30% | -14.744M -13.83% | -26.433M -79.28% | -56.705M -114.53% | N/A | N/A | N/A -66.48% | N/A -27.27% | N/A -31.58% | N/A -9.01% | N/A 145.67% | N/A 509.75% | N/A 114.40% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -315.00 99.75% | -270.00 14.29% | -218.53 19.06% | -255.00 -16.69% | -1,248.15 -389.47% | -362.30 70.97% | -88.75 75.50% | N/A 98.70% | N/A -34.51% | N/A -14.47% | N/A 5.17% | N/A 127.27% | N/A 391.11% | N/A 70.14% |
All data in USD
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -0.42 92.18% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -7.09M -73.20% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.59 93.59% | -0.33 | -0.26 | -80.76% |
| Q2 2024 Q2Q % growth | -3.37 91.08% | -1.58 | -1.79 | -113.16% |
| Q1 2024 Q2Q % growth | -0.64 98.24% | -2.48 | 1.84 | 74.18% |
| Q4 2023 Q2Q % growth | -5.35 97.18% | -4.12 | -1.23 | -29.99% |
| Q3 2023 Q2Q % growth | -9.20 -150.55% | -12.55 | 3.35 | 26.67% |
| Q2 2023 Q2Q % growth | -37.80 28.00% | -21.22 | -16.58 | -78.17% |
| Q1 2023 Q2Q % growth | -36.40 73.74% | -43.45 | 7.05 | 16.23% |
| Q4 2022 Q2Q % growth | -189.40 -3.24% | -59.26 | -130.14 | -219.60% |
| Q3 2022 Q2Q % growth | 18.20 102.65% | -21.49 | 39.69 | 184.69% |
| Q2 2022 Q2Q % growth | -52.50 84.38% | -136.02 | 83.52 | 61.40% |
| Q1 2022 Q2Q % growth | -138.60 -230.00% | -113.53 | -25.07 | -22.09% |
| Q4 2021 Q2Q % growth | -183.45 -97.26% | -162.08 | -21.38 | -13.19% |
| Q3 2021 Q2Q % growth | -686.70 -1,246.47% | -171.36 | -515.34 | -300.74% |
| Q2 2021 Q2Q % growth | -336.00 -558.82% | -155.30 | -180.70 | -116.36% |
| Q1 2021 Q2Q % growth | -42.00 30.00% | -22.19 | -19.82 | -89.32% |
| Q4 2020 Q2Q % growth | -93.00 -539.97% | -41.62 | -51.38 | -123.47% |
| Q3 2020 Q2Q % growth | -51.00 | -41.62 | -9.38 | -22.55% |
| Q2 2020 Q2Q % growth | -51.00 32.00% | -32.44 | -18.56 | -57.23% |
| Q1 2020 Q2Q % growth | -60.00 23.08% | -35.96 | -24.05 | -66.88% |
| Q4 2019 Q2Q % growth | -14.53 | -48.96 | 34.43 | 70.32% |
| Q3 2019 Q2Q % growth | -51.00 | -48.20 | -2.80 | -5.82% |
| Q2 2019 Q2Q % growth | -75.00 | -65.79 | -9.21 | -14.00% |
| Q1 2019 Q2Q % growth | -78.00 | -54.06 | -23.94 | -44.28% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |